Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies Sticks to Its Buy Rating for Gilead Sciences (GILD)
Morgan Stanley Adjusts Price Target on Gilead Sciences to $84 From $79
Morgan Stanley Remains a Hold on Gilead Sciences (GILD)
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $100
Gilead Sciences Is Maintained at Overweight by JP Morgan
Gilead Sciences Analyst Ratings
Raymond James Adjusts Gilead Sciences Price Target to $95 From $94
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $100
Analysts Offer Insights on Healthcare Companies: Accolade (ACCD) and Gilead Sciences (GILD)
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Gilead Sciences Analyst Ratings
Gilead Upgraded to Overweight by Wells Fargo, PrEP Launch Cited
Wells Fargo Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $100
Gilead Sciences (GILD) Was Upgraded to a Buy Rating at Wells Fargo
Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD)
Gilead Sciences Analyst Ratings
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $123 From $119, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
No Data
No Data